López-Gatius F, Santolaria P, Yániz J, Rutllant J, López-Béjar M
Animal Production, University of Lleida, Spain.
Theriogenology. 2001 Sep 1;56(4):649-59. doi: 10.1016/s0093-691x(01)00596-9.
Anestrus is common during the postpartum period in high-producing dairy cows. In a previous investigation, we were able to diagnose persistent follicles of 8 to 12 mm in anestrous cows. This report describes 2 consecutive studies. The objectives of the first were to 1) assess the association of persistent follicles with anestrus; and 2) evaluate 2 therapeutic treatments. In the second study, we compared the effectiveness of the best treatment established in Study 1 with the Ovsynch protocol. For Study 1, anestrous cows were considered to have a persistent follicle if it was possible to observe a single follicular structure > 8 mm in the absence of a corpus luteum or a cyst in 2 ultrasonographic examinations performed at an interval of 7 d. At diagnosis (Day 0), cows were assigned to 1 of 3 treatment groups. Cows in Group GnRH/PGF (n=17) were treated with 100 microg GnRH i.m., and 25 mg PGF2alpha i.m. on Day 14. Cows in Group PRID (n=18) were fitted with a progesterone releasing intravaginal device (PRID, containing 1.55 g of progesterone) for 9 d and were given 100 microg GnRH i.m. at the time of PRID insertion, and 25 mg PGF2alpha i.m. on Day 7. Cows in Group Control (n=18) received no treatment. The animals were inseminated at observed estrus and were monitored weekly by ultrasonography until AI or 5 weeks from diagnosis. Blood samples were also collected on a weekly basis for progesterone determination. The mean size of persistent follicles on Day 0 was 9.4 +/- 0.04 mm. Progesterone levels were < 0.2 ng/mL during the first 35 d in 16 of 18 Control cows. Cows in the PRID group showed a lower persistent follicle rate (16.7% < 70.6% < 88.9%; P < 0.0001; PRID vs GnRH/PGF vs Control, respectively); a higher estrus detection rate (83.3% > 29.4% > 11.1%; P < 0.0001) and a higher pregnancy rate (27.8% > 5.9% > 0%; P = 0.02). For the second study, 145 cows with persistent follicles were randomly assigned to 1 of 2 treatment groups: cows in Group Ovsynch (n=73) were treated with 100 microg GnRH i.m. on Day 0, 25 mg PGF2alpha i.m. on Day 7, and 100 microm GnRH i.m. 32 h later. Cows in this group were inseminated 16 to 20 h after the second GnRH dose (Ovsynch protocol). Cows in Group PRID (n=72) were treated as those in the PRID group of Study 1, and were inseminated 56 h after PRID removal. Cows in the PRID group showed a higher ovulation rate (84.8% > 8.2%: P < 0.0001); a higher pregnancy rate (34.2% > 4.1%; P < 0.0001) and lower follicular persistence rate (22.2% < 63%; P < 0.0001) than those in Ovsynch. Our results indicate that persistent follicles affect cyclic ovarian function in lactating dairy cows. Cows with persistent follicles can be successfully synchronized and time inseminated using progesterone, GnRH and PGF2alpha but show a limited response to treatment with GnRH plus PGF2alpha.
在高产奶牛的产后阶段,乏情现象很常见。在之前的一项调查中,我们能够诊断出处于乏情期奶牛的持续卵泡大小为8至12毫米。本报告描述了两项连续的研究。第一项研究的目的是:1)评估持续卵泡与乏情的关联;2)评估两种治疗方法。在第二项研究中,我们将第一项研究中确定的最佳治疗方法与Ovsynch方案的有效性进行了比较。对于第一项研究,如果在间隔7天进行的两次超声检查中,在没有黄体或囊肿的情况下能够观察到单个卵泡结构大于8毫米,则认为乏情期奶牛有持续卵泡。在诊断时(第0天),将奶牛分配到3个治疗组中的1组。GnRH/PGF组(n = 17)的奶牛在第14天接受100微克促性腺激素释放激素(GnRH)肌肉注射和25毫克前列腺素F2α(PGF2α)肌肉注射。PRID组(n = 18)的奶牛佩戴含1.55克孕酮的孕酮释放阴道装置(PRID)9天,在插入PRID时接受100微克GnRH肌肉注射,并在第7天接受25毫克PGF2α肌肉注射。对照组(n = 18)的奶牛不接受治疗。在观察到发情时对动物进行输精,并通过超声每周监测一次,直到人工授精或诊断后5周。每周还采集血样用于测定孕酮。第0天持续卵泡的平均大小为9.4±0.04毫米。18头对照组奶牛中,有16头在最初35天内孕酮水平<0.2纳克/毫升。PRID组的奶牛持续卵泡率较低(分别为16.7%<70.6%<88.9%;P< 0.0001;PRID组与GnRH/PGF组与对照组相比);发情检出率较高(83.3%>29.4%>11.1%;P< 0.0001),妊娠率较高(27.8%>5.9%>0%;P = 0.02)。对于第二项研究,145头有持续卵泡的奶牛被随机分配到2个治疗组中的1组:Ovsynch组(n = 73)的奶牛在第0天接受100微克GnRH肌肉注射,在第7天接受25毫克PGF2α肌肉注射,并在32小时后接受100微克GnRH肌肉注射。该组奶牛在第二次GnRH注射后16至20小时进行输精(Ovsynch方案)。PRID组(n = 72)的奶牛与第一项研究的PRID组奶牛治疗方法相同,并在取出PRID后56小时进行输精。PRID组的奶牛排卵率较高(84.8%>8.2%: P< 0.0001);妊娠率较高(34.2%>4.1%;P< 0.0001),卵泡持续率低于Ovsynch组(22.2%<63%;P< 0.0001)。我们的结果表明,持续卵泡会影响泌乳奶牛的卵巢周期功能。有持续卵泡的奶牛使用孕酮、GnRH和PGF2α可以成功同步发情并定时输精,但对GnRH加PGF2α治疗的反应有限。